Oncolytics Biotech Updates GOBLET Data, 29% Patient Benefit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ONCY?
Oncolytics Biotech announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma, SCAC, a setting with no U.S. Food and Drug Administration-approved treatment options. Previous analysis from this cohort has focused on second-line or later SCAC patients. As of the current data cut, four of 14 evaluable third-line patients receiving pelareorep and atezolizumab achieved objective responses, resulting in an objective response rate of approximately 29%. These responses included two complete responses and two partial responses. The median duration of response is approximately 17 months, indicating both depth and durability of clinical benefit in a heavily pretreated population. "As we continue to analyze the Goblet data, we are finding important trends that are helping to shape our clinical development strategy," said Jared Kelly, Chief Executive Officer of Oncolytics. "When you isolate to anal cancer patients with two prior lines of treatment and see a strong signal like this, it points the arrow in a direct line to a registration study in an indication where there are no FDA-approved therapies. We already had good data here, but looking closer, it becomes clearer that we can make an immediate impact on patients' lives who have no options."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.977
Low
3.00
Averages
5.50
High
10.00
Current: 0.977
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Clinical Trial Surge: In 2024, over 2,100 oncology clinical trials were initiated globally, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 10% response rate of standard treatments, which will expedite its approval process.
- Significant Survival Extension: Patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, suggesting a potential market value of $3 billion to $5 billion for this difficult-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expansion plans, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, demonstrating the company's commitment to advancing its clinical development initiatives.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Oncolytics Biotech Receives FDA Fast Track Designation
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer, which is expected to expedite the approval process and enhance market competitiveness.
- Clinical Data Advantage: The 33% response rate of pelareorep combined with standard chemotherapy significantly surpasses the 10% rate of chemotherapy alone, with a median survival of 27 months, indicating its potential value in hard-to-treat cancer populations.
- Significant Market Opportunity: The annual revenue for second-line treatment of KRAS-mutant colorectal cancer ranges between $3 billion and $5 billion, positioning Oncolytics' innovative therapy to capture a substantial share in this rapidly growing market.
- Team Expansion and Strategic Positioning: Oncolytics Biotech has recently appointed two executives to support its expansion plans, demonstrating the company's commitment to future clinical trials and market outreach, thereby strengthening its leadership position in the biotech sector.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Surge in Clinical Trials: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, highlighting the drug's potential market value of up to $5 billion in a challenging cancer segment.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, reflecting the company's commitment to expanding its clinical development efforts and enhancing operational capabilities.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Cancer Treatment
- Clinical Trial Surge: In 2024, over 2,100 oncology clinical trials were initiated globally, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA, based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 10% response rate of standard treatments, which will expedite its approval process.
- Significant Survival Extension: Patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, suggesting a potential market value of $3 billion to $5 billion for this difficult-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expansion plans, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, demonstrating the company's commitment to advancing its clinical development initiatives.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Oncolytics Biotech Receives FDA Fast Track Designation
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer, which is expected to expedite the approval process and enhance market competitiveness.
- Clinical Data Advantage: The 33% response rate of pelareorep combined with standard chemotherapy significantly surpasses the 10% rate of chemotherapy alone, with a median survival of 27 months, indicating its potential value in hard-to-treat cancer populations.
- Significant Market Opportunity: The annual revenue for second-line treatment of KRAS-mutant colorectal cancer ranges between $3 billion and $5 billion, positioning Oncolytics' innovative therapy to capture a substantial share in this rapidly growing market.
- Team Expansion and Strategic Positioning: Oncolytics Biotech has recently appointed two executives to support its expansion plans, demonstrating the company's commitment to future clinical trials and market outreach, thereby strengthening its leadership position in the biotech sector.
See More
Precision Biologics Market Awakens to $71 Billion Opportunity
- FDA Acceleration: Oncolytics Biotech's cancer treatment pelareorep has received Fast Track Designation from the FDA for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, demonstrating a 33% response rate significantly higher than the 10% seen with traditional chemotherapy, which will expedite its approval process and enhance market competitiveness.
- Survival Extension: Clinical data shows that patients treated with pelareorep have a median survival of 27 months compared to 11.2 months with standard treatment, indicating the drug's potential market value in hard-to-treat cancer populations, with the global second-line treatment market estimated between $3 billion and $5 billion annually.
- Leadership Team Expansion: Oncolytics Biotech recently appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics to manage expanding clinical programs, reflecting the company's commitment to future growth and readiness.
- Clinical Trial Plans: The company plans to launch a controlled study in March 2026 comparing standard treatment with pelareorep, with interim data expected by year-end, further validating its efficacy in colorectal cancer treatment.
See More
